Selected synthetic case / actual retained answers
A blocker identifies a pathway, not necessarily the mutated gene
Both tools identify hereditary xerocytosis. MontMedical makes the sharper distinction between Gardos-channel involvement and proof of a KCNN4 mutation.
A selected synthetic development case, published by MontMedical. The clinical fingerprints match, but the exact prompts submitted to OpenEvidence were not independently retained. This is an editorial comparison of historical answers, not a blinded efficacy trial.
Our editorial assessment
How the retained answers rate.
OpenEvidence7.8/10
MontMedical8.4/10
MontMedical is stronger on the gene-versus-pathway distinction.
Same five criteria and weights for both systems| Criterion and weight | OpenEvidence | MontMedical |
|---|
| Diagnosis and case fit 25% | 9/10 | 9/10 |
|---|
| Interpretation of tests and experiments 25% | 7/10 | 9/10 |
|---|
| Strength of the claims 20% | 6/10 | 8/10 |
|---|
| Decisions and next steps 15% | 9/10 | 7/10 |
|---|
| Clarity and teaching 15% | 8/10 | 8/10 |
|---|
Why each criterion received its mark
Diagnosis and case fit
OpenEvidence · 9/10: Correctly unifies dehydration, haemolysis, iron loading and sample-dependent potassium.
MontMedical · 9/10: Correctly identifies the red-cell disorder and why HFE heterozygosity is insufficient.
Interpretation of tests and experiments
OpenEvidence · 7/10: The broad opening allows either gene, but later blocker interpretation moves too far towards KCNN4-associated DHS type 2.
MontMedical · 9/10: Explicitly distinguishes primary KCNN4 dysfunction from Gardos activation downstream of PIEZO1.
Strength of the claims
OpenEvidence · 6/10: Several exclusions and the subtype inference are stronger than the supplied testing warrants.
MontMedical · 8/10: Avoids the gene-level over-inference, though its general splenectomy wording compresses genotype-specific evidence.
Decisions and next steps
OpenEvidence · 9/10: Makes the surgical issue prominent and proposes ektacytometry and channel-gene testing.
MontMedical · 7/10: Addresses the surgical pitfall, but provides less explicit confirmatory work-up than OpenEvidence.
Clarity and teaching
OpenEvidence · 8/10: Connected physiological account; additional assertions make the account longer and more categorical.
MontMedical · 8/10: Concise and organised; the channel relationship could be taught more fully.
AI-assisted editorial judgment of these historical texts, published by MontMedical. Read the rubric, anchors and limits. These are answer-quality scores, not measured diagnostic accuracy or patient benefit.
The actual retained wording
OpenEvidence vs MontMedical.
These are verbatim passages from the retained answers, not rewritten examples. Bold, link formatting and line breaks have been removed. Each labelled passage is contiguous; an excerpt may begin within a sentence. Our interpretation and scores are separate.
OpenEvidence
Retained 2026-09-12
Leading classification
Dehydrated hereditary stomatocytosis (hereditary xerocytosis) due to a red-cell cation-leak channelopathy (PIEZO1 or Gardos/KCNN4) is the diagnosis that unifies this entire picture — not HFE hemochromatosis, and not a membrane disorder amenable to splenectomy.
Blocker inference
The functional experiment showing that a Gardos-channel blocker corrects the excess potassium loss from her washed erythrocytes directly implicates KCNN4/Gardos-channel-mediated leak, consistent with DHS type 2.
MontMedical
Retained 2026-09-12
Leading classification
The patient has dehydrated hereditary stomatocytosis (hereditary xerocytosis), presenting with chronic compensated non-autoimmune hemolysis, erythrocyte dehydration (MCHC 36.7 g/dL), severe hepatic iron overload, and temperature-dependent pseudohyperkalemia.
Blocker inference
Although ex vivo inhibition of the calcium-activated potassium channel markedly reduces red-cell potassium loss, this finding does not distinguish a primary KCNN4 gain-of-function variant from secondary downstream Gardos channel activation driven by calcium influx through PIEZO1.
The case and the decision
The synthetic case combines compensated haemolysis, dehydrated red cells, iron overload and a potassium rise after blood is left unseparated. A Gardos-channel blocker reduces potassium loss from washed cells. Neither channel gene has been sequenced.
Where MontMedical gives the stronger account
OpenEvidence correctly names the broad PIEZO1-or-KCNN4 channelopathy in its opening. Later, its description of the blocker result moves towards DHS type 2, the KCNN4-associated subtype.
MontMedical explicitly explains the alternative: the Gardos potassium channel may be the primary defect, or it may be activated downstream of calcium entry through abnormal PIEZO1. Blocking the common downstream route can improve either mechanism.
The experiment that makes this concrete
This is more than a theoretical objection. Rapetti-Mauss and colleagues studied PIEZO1-mutant cells without a detected KCNN4 mutation. KCNN4 inhibitors reduced excess potassium loss and prevented dehydration. The response therefore supports Gardos-pathway involvement without uniquely identifying a KCNN4 mutation. [1]
The relevant next question is which gene is altered, addressed by suitable molecular testing and interpretation alongside the cell phenotype.
What OpenEvidence gets right
Its explanation of the red-cell cation leak is clear, and it brings the proposed splenectomy into focus early. Both answers recognise the disease pattern. The narrower MontMedical advantage is avoiding an unsupported subtype assignment; this example does not compare surgical outcomes or establish a product-wide diagnostic win.
Retained answer dates: MontMedical 2026-09-12; OpenEvidence 2026-09-12. Excerpt wording was checked against the retained answers; formatting was removed. These versions were selected during development. Complete original run settings and identical submitted prompts are not documented.
This article examines the MontMedical Pro beta using retained diagnostic answers.